John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, shares some insights into the randomized Phase II Canadian Cancer Trials Group (CCTG) LY.17 study, which is evaluating novel salvage therapy pre-autologous stem cell transplantation (autoSCT) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Patients in this trial were randomized to receive either rituximab combined with gemcitabine, dexamethasone and cisplatin (R‐GDP), or rituximab plus dose-intensified cyclophosphamide, etoposide and cisplatin (R-DICEP). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.